Coherion provides a predictive modeling platform that uses proprietary quantum‑informed simulations and universal coherence algorithms to assess drug candidates, synthetic proteins, and advanced materials entirely in silico. The service delivers binding affinity, toxicity, stability, and failure predictions as validated dossiers and IND‑readiness packages, and also offers licensable engine modules for organizations to run these analyses internally.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery, protein engineering, and advanced material development rely on costly, time‑intensive experimental testing and high‑performance computing resources, leading to long development cycles and uncertain outcomes.
Solution
Coherion offers a predictive modeling platform that uses proprietary quantum‑informed simulations and universal coherence algorithms to evaluate molecular behavior, protein stability, and material performance in silico. The service generates binding affinity, toxicity, and stability assessments for drug candidates, coherence scores and degradation forecasts for synthetic proteins and fusion constructs, and quantum lattice predictions for materials used in aerospace, clean energy, and defense. Results are delivered as validated dossiers and IND‑readiness packages, enabling faster decision‑making and reduced reliance on wet‑lab experiments. Coherion also provides a licensable engine for organizations to run these predictions internally, as well as commercial‑ready repurposed drug IP for immediate licensing.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking pre‑clinical validation, as well as aerospace, clean‑energy, and defense firms developing advanced materials that require high‑fidelity predictive analytics.
Features
- Binding affinity and target fit modeling for novel compounds, with toxicity and commercial viability predictions
- Thermal and entropic stress simulations for proteins and fusion constructs, including degradation forecasts and stability‑enhancement recommendations
- Quantum‑coherence lattice framework that predicts material structure, stress response, and failure under extreme conditions
- Coherion Cert™ validated dossiers and IND readiness packages for regulatory submission support
- RevivorX™ repurposed drug IP licensing kits with method‑of‑use patents and revenue‑share or milestone options
- Licensable Coherion Engine™ modules for drug screening, fusion design, and quantum material modeling, protected by strict license controls